Objectives: In the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial, a single dose of tenofovir disoproxil fumarate and emtricitabine was taken orally 2-24 h before sexual intercourse. A sub-study was conducted to assess the pharmacokinetics of tenofovir and emtricitabine in blood, saliva and rectal tissue following this initial oral intake.
Introduction
The use of oral tenofovir disoproxil fumarate/emtricitabine is recommended for HIV pre-exposure prophylaxis (PrEP) in high-risk individuals. 1 -3 Most PrEP trials have tested the daily use of one combined pill of 300 mg tenofovir disoproxil fumarate/200 mg emtricitabine with various levels of effectiveness due to different rates of adherence. 4 -10 In the ANRS IPERGAY trial, a different PrEP regimen was tested in MSM in France and Canada, in order to improve adherence and consequently effectiveness. PrEP was taken 'on demand' according to sexual activity with dosing before and after sex, an approach that was found to be highly effective. 11 In that trial, participants were instructed to take a loading dose of two pills of tenofovir disoproxil fumarate/emtricitabine 2 -24 h before sexual intercourse, and two additional pills after sexual intercourse (one pill 24 h after the first intake and one pill 24 h later) as suggested by animal models. 12, 13 A pharmacokinetic sub-study was performed in the ANRS IPERGAY trial to assess whether drug levels in plasma, PBMCs, rectal tissue and saliva following a single loading dose of two pills of tenofovir disoproxil fumarate/emtricitabine were appropriate. In addition ex vivo HIV-1 challenges of rectal biopsies were also performed to assess tissue infectibility before and after dosing.
Methods

Participants
The ANRS IPERGAY trial was a randomized placebo-controlled trial conducted in France and Canada which assessed the efficacy and safety of 'on demand' PrEP with tenofovir disoproxil fumarate/emtricitabine in highrisk HIV-negative adult MSM and reported a 86% reduction of HIV incidence with tenofovir disoproxil fumarate/emtricitabine as compared with placebo. 11 A pharmacokinetic sub-study was proposed to 12 participants after screening for the main study, but before randomization. Eligible participants were HIV seronegative MSM, aged 18 years or older, at high risk for HIV acquisition defined as unprotected anal sex with at least two different partners over the last 6 months. Main exclusion criteria included hepatitis B surface antigen positivity, a creatinine clearance ,60 mL/min as assessed by the Cockroft -Gault formula, and an ALT level .2.5 times the upper limit of normal.
Ethics
The protocol was approved by public health authorities and by ethics committees in France (CPP Ile de France IV, Paris) (approval reference number: 2011/26). All participants provided informed written consent to participate in this pharmacokinetic sub-study.
Study design
This pharmacokinetic sub-study was carried out at a single study site (Saint-Louis Hospital, Paris). Participants arrived in the morning fasting and were given two pills of tenofovir disoproxil fumarate/emtricitabine orally (each pill contained 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine). A meal was provided 3 -4 h after dosing. Study drugs were donated by Gilead Sciences Inc. (Foster City, CA, USA). Blood and saliva samples were collected at 0 h (pre-dose) and at 0.5, 1, 2, 4, 8 and 24 h after dosing for determination of plasma and saliva pharmacokinetic parameters. At 2 and 24 h after dosing, PBMCs were also collected to assess intracellular levels of tenofovir diphosphate (DP) and emtricitabine triphosphate (TP). Additional blood samples were obtained 7 and 14 days after dosing and plasma and PBMCs were collected and stored. In addition, in order to assess drug penetration in the rectal tissue and ex vivo HIV infectibility of the rectal biopsies, each participant underwent two rounds of rectal biopsies. One round was performed before dosing ( 30 min) and a second round after dosing with two participants having biopsies taken at the same timepoint post-dose (0.5, 1, 2, 4, 8 and 24 h). At each timepoint six rectal biopsies were collected: two for measuring tenofovir and emtricitabine drug levels, and four to perform ex vivo HIV-1 challenges. Participants were instructed to avoid condomless anal intercourse for at least 1 week following the biopsy procedure to allow full healing. Before being randomized in the main trial participants were screened again 4 weeks later and none acquired HIV infection. Seven HIV-infected patients on stable tenofovir disoproxil fumarate/emtricitabine-containing ART also had rectal biopsies performed to assess emtricitabine and tenofovir drug levels in rectal tissue, and served as controls.
Safety evaluation
Subjects were monitored for 48 h after dosing. Clinical assessments were performed and signs and symptoms were recorded by using the ANRS toxicity grading scale. 14 
Sample collection and processing
Blood
Blood sampling was drawn in BD EDTA Vacutainer w blood collection tubes; plasma was collected after centrifugation at 3000 g for 10 min at 48C and stored at 2208C until further analysis. Blood was also drawn in BD Na-citrate Vacutainer w cell preparation tubes and centrifuged at 1800 g for 25 min at 20 -258C. PBMCs were collected from the buffy coat and cell pellets were lysed with 1 mL of cold (2-88C) 70% methanol and stored immediately at 2808C until further analysis, as previously described. 15 
Saliva
Saliva was sampled simultaneously to blood using Salivette w (Sarstedt, Numbrecht, Germany). Participants removed the swab from the Salivette w , chewed it for 60 s and returned the swab with the absorbed saliva to the Salivette w . Centrifugation for 10 min at 1000 g yielded at least 1 mL of clear saliva that was aliquotted and stored at 2208C.
Rectal biopsies
Rectal biopsies were collected through a rigid rectoscope. Biopsies were performed 8 -12 cm from the anus. Six biopsies were taken from each patient twice, before and after dosing. Four biopsies were placed immediately in complete medium [DMEM/Glutamax (Gibco) supplemented with 10% FCS, 20 mg/L gentamicin, 40 mg/L piperacillin and 0.5 mg/L amphotericin], and were sent to the virology laboratory within 1 h to perform ex vivo HIV-1 challenges. Two additional biopsies were put in sterile tubes and immediately frozen at 2808C until being analysed for drug concentration assays.
Drug concentration analysis
We used thawed plasma and saliva aliquots and thawed rectal biopsies for analysis. Rectal biopsies were homogenized before analysis. Tenofovir and emtricitabine levels were measured centrally after a simple protein precipitation, by HPLC with tandem MS (HPLC-MS/MS) as previously described. 16 Both assays were fully validated according to current guidelines for bioanalytical method validation defined by the EMA. The plasma assay was linear over the range of 1 [lower limit of quantification (LLOQ)] to 1000 mg/L [upper limit of quantification (ULOQ)] for tenofovir and 2 (LLOQ) to 5000 mg/L (ULOQ) for emtricitabine. The saliva assay was linear over the range of 0.25 (LLOQ) to 50 mg/L (ULOQ) for tenofovir and 2 (LLOQ) to 2000 mg/L (ULOQ) for emtricitabine. In rectal tissue, the LLOQ was 1.1 and 0.4 mg/g of tissue for tenofovir and emtricitabine, respectively.
For intracellular tenofovir-DP and emtricitabine-TP analyses, cell lysates were analysed as previously reported using a validated LC-MS/MS assay. 17 The tenofovir-DP and emtricitabine-TP LLOQ were 5 fmol and 0.1 pmol per sample, respectively. One or two aliquots were tested per participant at each timepoint.
All concentration measures were performed in batch, blinded to the sampling time and also to whether participants or controls samples were analysed.
Pharmacokinetic analysis
Tenofovir and emtricitabine pharmacokinetic parameters in plasma and saliva were calculated by a non-compartmental method (WinNonlin 6.3, Pharsight Corporation, Mountain View, CA, USA). The maximum concentration of drug observed in plasma (C max ) and the time to C max (T max ) were obtained from the plasma concentration -time curves. The area under the concentration -time curve from 0 to 24 h (AUC 0 -24 ) was calculated according to the linear up/log down trapezoidal rule. Given the small number of tenofovir-DP and emtricitabine-TP samples (2 and 24 h timepoints), data were summarized using medians and ranges. Similarly, for rectal tissue concentrations of tenofovir and emtricitabine (two biopsies per participant, two participants per timepoint), mean concentrations and standard deviations were presented. Data below the LLOQ were considered negative.
Ex vivo HIV infectivity assays
The experimental protocol is illustrated in Figure S1 (a) (available as Supplementary data at JAC Online). Fresh rectal biopsies were gently disrupted with a small disposable pestle and were centrifuged for 5 min at 600 g. The pellet was resuspended in a final volume of 200 mL DMEM/ Tenofovir/emtricitabine pharmacokinetics JAC Glutamax medium (Thermo Scientific, Villebon sur Yvette, France) supplemented with 2% FCS and 100 U/mL IL-2, and 50 ng of p24 antigen of the R5-tropic HIV-1 reference strain NL-AD8 were added. Twenty hours after virus exposure, the cells were centrifuged, washed three times with PBS, and treated with 0.05% trypsin -EDTA for 20 min at 378C to inactivate residual extracellular virus. Trypsin activity was then blocked by the addition of 1 mL of complete medium, and the cells were centrifuged. The cell pellet was resuspended in 1 mL of complete medium (final volume) containing 100 U IL-2 and 5×10 5 MT4-R5 cells and cultured in 12-well, flat-bottom plates to allow virus spread from infected cells to MT4-R5 cells over an 11 day period. Supernatants (300 mL) were collected every day and viral production was assessed by the measure of p24 antigen in the supernatant using an ELISA p24 (Innotest, Ingen) according to the manufacturer's instructions. A biopsy was considered to be infected if p24 antigen concentrations increased continuously above 0.02 ng/mL over the 11 day period, and the first day of infection was taken as the day the p24 antigen level crossed the 0.02 ng/mL threshold.
Statistical methods
To assess ex vivo HIV-1 infectivity of rectal biopsies after tenofovir disoproxil fumarate/emtricitabine dosing, we compared the number of participants who had a least one out of four rectal biopsies infected with HIV-1 before and after tenofovir disoproxil fumarate/emtricitabine dosing using a Mac Nemar test for clustered data. For this analysis we pooled data from all biopsies taken before or after dosing.
We also established a quantitative infectivity score for each rectal biopsy ranging from 0 (no HIV-1 infection detected up to day 11) to 6 (HIV-infection detected as soon as day 4 post-exposure) ( Figure S1b ). Mean scores were compared before and after dosing using a Wilcoxon signed rank test. P values of ,0.05 were deemed statistically significant.
Results
Participants
Twelve participants were enrolled in this pharmacokinetic substudy. They were all males with a median age of 31 years (IQR: 26 -34) and 10 were Caucasians. The median body weight was 76 kg (IQR: 60 -80), the median BMI was 25 kg/m 2 (IQR: 20 -26) and the median creatinine clearance was 122 mL/min (IQR: 98 -149). Clinical tolerability of this single high oral dose of tenofovir disoproxil fumarate/emtricitabine was good with no adverse events reported over 48 h post-dosing.
Blood pharmacokinetics of tenofovir and emtricitabine
Individual and median concentration -time curves are shown in Figure 1 . Median pharmacokinetic parameters are shown in Table 1 . Tenofovir and emtricitabine were detected in plasma up to 7 days post-dosing with median concentrations of 2.3 and 6.9 ng/mL, respectively.
Median tenofovir-DP concentrations in PBMCs were 12.2 (range: 3 -26) and 16.7 (range: 11 -26) fmol/10 6 cells at 2 and 24 h post-dosing, respectively. Four out of 12 (33%) participants at 2 h post-dosing and 7 out of 12 (58%) at 24 h post-dosing had levels at 16 fmol/10 6 or above. Median emtricitabine-TP concentrations in PBMCs were 2.8 (range: 1.3 -6.6) and 2 (range: 1.3 -3.5) pmol/10 6 cells at 2 and 24 h post-dosing, respectively. Tenofovir-DP and emtricitabine-TP remained detectable in all but one participant up to 2 weeks post-dosing.
Saliva pharmacokinetics of tenofovir and emtricitabine
Individual and median concentration -time curves are shown in Figure 2 . Median pharmacokinetic parameters are shown in Table 1 : emtricitabine has a saliva/plasma AUC 0 -24 ratio of 17%, whereas tenofovir has a low saliva/plasma AUC 0 -24 ratio of 2%.
Rectal tissue pharmacokinetics of tenofovir and emtricitabine
As shown in Figure 3 , emtricitabine was readily detectable in rectal biopsies as soon as 30 min after dosing and remained detectable up to 24 h, at mean concentrations that were similar to those obtained at steady state in HIV-infected patients receiving longterm tenofovir disoproxil fumarate/emtricitabine-based ART. Conversely, tenofovir concentrations were only detected at 24 h in rectal biopsies, at levels that appeared lower than those obtained in HIV-infected controls on tenofovir disoproxil fumarate/emtricitabine-based ART.
Ex vivo infectivity of rectal biopsies
Rectal biopsies were assessable for ex vivo HIV-1 infectibility for 10 of the 12 patients (bacterial contamination prevented further analyses for the remaining 2 patients). All 10 studied participants had at least one of the four pre-dosing biopsies infected as compared with only 6/10 post-dosing (P, 0.07). A similar trend was found using a quantitative infectibility score of rectal biopsies with a higher score per patient before than after dosing with a median difference of 1.38 (IQR: 0.25 -1.75) (P,0.07). This effect was seen with the first set of biopsies taken as early as 30 min and 1 h post-dosing with higher scores before (mean: 2.7) than after dosing (mean: 1.2), but due to the small number of participants tested we could not assess a clear relationship between the time of the biopsy and infectibility.
Discussion
Our study provides information regarding the pharmacokinetics of a single high dose of oral tenofovir disoproxil fumarate/emtricitabine (600 mg tenofovir disoproxil fumarate and 400 mg emtricitabine) in healthy participants enrolled in the ANRS IPERGAY PrEP trial. Following oral intake, tenofovir and emtricitabine were quickly detectable in plasma with a median T max obtained within 1 -2 h post-dosing, as previously reported in both HIV-positive and -negative individuals. 15,18 -21 These data are relevant regarding the timing of dosing in the ANRS IPERGAY trial where participants were instructed to take the first two pills at least 2 h before sexual intercourse, a time at which plasma concentrations of both drugs are well above the mean in vitro IC 50 for HIV-1 (10 -60 mg/L for tenofovir and 4 mg/L for emtricitabine). 18, 20, 22, 23 Tenofovir T max can be delayed, however, by 0.5-2 h when the drug is administered with food, and this may have clinical relevance for the optimal timing of the first dose, although there is an increase in the overall exposure when tenofovir disoproxil fumarate is dosed with food. 19, 20 Dose-escalating studies of tenofovir and emtricitabine have reported dose-proportional increases in tenofovir and emtricitabine pharmacokinetic parameters in plasma, and the high C max Fonsart et al.
and AUC 0 -24 levels reported in our study following the oral intake of a double dose of tenofovir disoproxil fumarate/emtricitabine were in the range of those previously reported. 15,19 -21,24 Also, median plasma C 24 levels of both tenofovir and emtricitabine (40 and 63 mg/L, respectively) in our study remained in the range or above the in vitro IC 50 for HIV-1, suggesting that this single double-dose of tenofovir disoproxil fumarate/emtricitabine provides adequate plasma concentrations for up to 24 h postdosing, when participants in the trial were instructed to take their post-exposure pills.
It is, however, unclear whether plasma drug exposure is associated with in vivo protection from sexual acquisition of HIV-1. Intracellular concentrations of the active metabolites of tenofovir, i.e. tenofovir-DP, and of emtricitabine, i.e. emtricitabine-TP, which have direct anti-HIV-1 activities, have been suggested as better correlates of protection. A regression analysis performed in the Iprex study reported that tenofovir-DP concentrations in PBMCs above 16 fmol/10 6 cells (95% CI: 3 -28) were indeed associated with a 90% reduction in the risk of HIV-1 acquisition with tenofovir disoproxil fumarate/emtricitabine relative to placebo. 17 For Tenofovir/emtricitabine pharmacokinetics JAC emtricitabine-TP the corresponding values were 3.7 (95% CI: 1.2-6.1) pmol/10 6 PBMCs. 17 In our study, median PBMC tenofovir-DP levels .16 fmol/10 6 cells were obtained in only 33% and 58% of participants at 2 and 24 h post-dose, respectively. However, all concentrations of tenofovir-DP and emtricitabine-TP at 2 and 24 h post-dosing remained above the lower bound of these CIs. Furthermore, subsequent analysis of the open-label extension of the Iprex study revealed that tenofovir-DP exposure in dried blood spots consistent with two or three doses per week of tenofovir disoproxil fumarate/emtricitabine achieved 90% protection in MSM, which emulates the ANRS IPERGAY dosing regimen in which four pills had to be taken over 72 h following sexual intercourse. 25 Also, in the STRAND study, the use of two or four pills per week in healthy volunteers was associated with tenofovir-DP levels in PBMCs (median 11 and 32 fmol/10 6 cells, respectively) consistent with a 76% and 96% reduction in the risk of HIV-1 acquisition, respectively. 17 Similarly, in the CellPrEP study, where healthy volunteers received a daily pill of tenofovir disoproxil fumarate/ emtricitabine, the inferred risk reduction in HIV-1 acquisition based on PBMC tenofovir-DP was 77% after one dose, 96% after three doses and 99% after five doses. 26 In that study only 30% of the participants achieved the Iprex threshold of 16 fmol/10 6 cells after one dose, and 55% after three doses, as compared with 58% at 24 h in our study after a single double-dose, suggesting the potential of this double-dose to provide high protection against HIV. 24 It remains, however, difficult to compare tenofovir-DP and emtricitabine-TP results across studies as the cell processing and dosing differences can create some biases. Indeed, tenofovir-DP concentrations measured in viably cryopreserved PBMCs as in Iprex are usually lower than those obtained from PBMC samples processed and lysed immediately as in CellPrEP and our study. 17 Overall, our data suggested that a single doubledose of tenofovir disoproxil fumarate/emtricitabine provides plasma concentrations of both drugs above the IC 50 for HIV-1 as soon as 2 h after dosing, and that intracellular concentrations of their active metabolites reached levels similar to those reported with three consecutive doses of oral tenofovir disoproxil fumarate/ emtricitabine in the CellPrEP study, which were associated with a 96% risk reduction of HIV acquisition. 26 Assessing drug concentrations in the tissues, and rectal tissue in particular for MSM, might provide an even better assessment of HIV-1 protection although precise target concentrations have not yet been defined. 27 Interestingly, emtricitabine was detected in rectal biopsies as early as 30 min following oral intake of tenofovir disoproxil fumarate/emtricitabine in our study, at levels that were similar to those found in HIV-1-infected patients receiving longterm tenofovir disoproxil fumarate/emtricitabine-based regimens (Figure 3 ). However, tenofovir was not detected in rectal biopsies until 24 h post-dosing, underlying the pharmacokinetic differences between these two drugs in terms of tissue distribution, as previously reported also in the female genital tract, CSF or in breast milk. 15, 21, 23, 28 These data of the delayed penetration of tenofovir in rectal tissue are consistent with those reported in animal models where emtricitabine was rapidly detected in rectal secretions after oral challenge with tenofovir disoproxil fumarate/emtricitabine, whereas tenofovir was only detected at 24 h post-dose. 13 This finding of a rapid penetration of emtricitabine in rectal tissue as compared with tenofovir is critical for the design of on-demand PrEP regimens since it suggests, first, that emtricitabine should be used in combination with tenofovir, and second, that the recommendation of taking the first two pills at least 2 h before sex is sufficient to allow emtricitabine to reach high levels in the rectal compartment. In a recent study, emtricitabine was also detected at high concentrations at 6 h post-dose (first timepoint assessed) as compared with tenofovir, again suggesting a differential penetration of both drugs in the rectal tissue. 21 Also, this pharmacokinetic/pharmacodynamics study aimed at determining the number of tenofovir disoproxil fumarate/emtricitabine doses required to achieve rectal tissue concentrations of the active metabolites (tenofovir-DP and emtricitabine-TP) associated with protection from HIV infection of CD4 T cells ex vivo. Using the ANRS IPERGAY regimen of a double dose of tenofovir disoproxil Fonsart et al.
fumarate/emtricitabine, the investigators predicted that 81% and 98% of the population at 2 and 24 h post-dosing, respectively, would achieve target concentrations in the rectal tissue associated with 90% protection from HIV-1 infection. 21 Because of a lack of a definitive pharmacokinetic target in rectal tissue, ex vivo infectivity assays were performed in our study as they could be a valuable surrogate of HIV protection. 27 Our study found a trend toward early (as soon as 30 min) but partial protection of rectal biopsies from HIV-1 infection following a doubledose of tenofovir disoproxil fumarate/emtricitabine which might be related in part to the rapid penetration of emtricitabine in the rectal tissue. Indeed, in a previous study with tenofovir disoproxil fumarate alone, no protection from HIV challenges was observed up to 24 h post-dosing. 27 These data again suggest that this initial partial protection from HIV-infection ex vivo was mainly due to emtricitabine and support both the recommendation of using a combination of tenofovir disoproxil fumarate and emtricitabine for on-demand PrEP and the ANRS IPERGAY dosing regimen with a first pill intake at least 2 h before sex. The partial protection we report in this study is also a reminder that pre- Tenofovir/emtricitabine pharmacokinetics JAC exposure doses alone are not sufficient to provide full protection against HIV infection and that post-exposure doses are required as recommended in the ANRS IPERGAY dosing regimen. Indeed, data from animal models suggest that post-exposure doses are critical to confer high protection against rectal SHIV challenges.
12,13
Finally, we measured in our study the diffusion of tenofovir and emtricitabine in saliva as oral transmission of HIV-1 may occur, especially among high-risk MSM who rarely use condoms for oral sex. 29, 30 In agreement with a preliminary report in HIV-infected patients receiving tenofovir disoproxil fumarate/ emtricitabine-based ART, emtricitabine diffusion in saliva in our study was good (17% of plasma exposure), with levels remaining above the virus IC 50 concentration, whereas tenofovir diffusion was poor (2% of plasma exposure), with low levels unlikely to be protective against HIV-1 acquisition through an oral route, suggesting again the potential benefit of combining both drugs. 16 This drug combination might not be necessary, however, in men and women using a daily PrEP regimen, and no significant differences in efficacy was found between tenofovir disoproxil fumarate and tenofovir disoproxil fumarate/emtricitabine in a large randomized trial. 31 Our study has many limitations, first and foremost, its small size with only 12 participants. Also, the intracellular pharmacokinetics of tenofovir and emtricitabine were only performed in PBMCs at a few timepoints and not in rectal tissue. Finally, our ex vivo model of rectal biopsies challenged with HIV-1 is different from those previously reported since we disrupted the rectal biopsies prior to viral exposure and used an indicator cell line, and although no gold standard has been established, we did not perform a comparative validation study. Indeed, ex vivo studies have not yet demonstrated their clinical relevance and should be interpreted with caution when used to inform product development as they could be misleading, providing false positive or false negative results. In summary our results are supportive of the dosing schedule we used in the ANRS IPERGAY study with a pre-exposure dose of two pills of tenofovir disoproxil fumarate/emtricitabine (600/400 mg) to be taken 2 -24 h before coitus which can achieve adequate drug concentrations in plasma, PBMCs, rectal tissue and saliva. However, this pre-exposure dose is insufficient to provide full protection against HIV infection of the rectal tissue. These data also underline the critical need for post-exposures doses so that people at risk take at least four pills of tenofovir disoproxil fumarate/emtricitabine to cover an act of sexual intercourse in order to be protected from HIV acquisition. Fonsart et al.
